Last reviewed · How we verify

CancerVax Corporation — Portfolio Competitive Intelligence Brief

CancerVax Corporation pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
CancerVax vaccine (CANVAXIN) CancerVax vaccine (CANVAXIN) phase 3 Therapeutic cancer vaccine MAGE-1, MAGE-3 (melanoma-associated antigens) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centre Leon Berard · 1 shared drug class
  2. Chiang Mai University · 1 shared drug class
  3. Chiltern Pesquisa Clinica Ltda · 1 shared drug class
  4. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
  5. Galena Biopharma, Inc. · 1 shared drug class
  6. Genocea Biosciences, Inc. · 1 shared drug class
  7. GlaxoSmithKline · 1 shared drug class
  8. Green Cross Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CancerVax Corporation:

Cite this brief

Drug Landscape (2026). CancerVax Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cancervax-corporation. Accessed 2026-05-16.

Related